Anavex Life Sciences Corp (FRA:12X1)
€ 3.495 0.164 (4.92%) Market Cap: 299.15 Mil Enterprise Value: 165.79 Mil PE Ratio: 0 PB Ratio: 2.31 GF Score: 34/100

Anavex Life Sciences Corp at JPMorgan Healthcare Conference Transcript

Jan 13, 2022 / 04:15PM GMT
Release Date Price: €12.6 (-2.33%)
Unidentified Analyst

Good morning and thank you for joining us today. My name is Michael, and I'm an associate in JPMorgan's Healthcare Group.

Before I introduce you to our presenter today, I want to call your attention to the blue button on your screen. This is where you'll submit questions that will be addressed during Q&A.

With that, I'm pleased to introduce you to Christopher Missling, CEO of Anavex.

Christopher U. Missling
Anavex Life Sciences Corp. - Chairman, President, CEO & Secretary

Thank you for the very kind introduction, and thank you for inviting us to this conference. Very excited to share with you our story today. Since we're a public company, I'd like you to read this. It's the second page, forward-looking statement.

So let me explain to you what we are doing. The Anavex platform is a platform for neurological diseases. What we understand so far is that neurological chronic diseases have an impaired housekeeping function and an impaired house homeostasis. So this homeostasis imbalance is chronic, and we can see

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot